Mutual funds heavily increased their stakes in Biocon and PB Fintech in July 2026, with Biocon receiving ₹3,300 crore in inflows. While the pharmaceutical sector remains in favor, investors should note that mid-cap valuations are currently high and companies like Biocon have faced recent profit pressure.
In July 2026, Indian mutual funds shifted their focus toward small and mid-cap stocks, with Biocon and PB Fintech emerging as key targets for fund managers. Biocon stood out as the most significant acquisition, drawing ₹3,300 crore in net mutual fund inflows. This surge in buying activity was largely tied to institutional investors absorbing a 5.64% stake in the pharmaceutical company that was sold off by Mylan, a subsidiary of Viatris, via block deals in the middle of the month.
PB Fintech, the parent company of Policybazaar, also saw increased institutional interest. HDFC Mutual Fund notably raised its holding in the company to 5.02% during the month. This trend of aggressive accumulation in mid-cap stocks occurred as the Nifty Pharma index registered a gain of nearly 20% by the end of July, with Biocon shares rising by 18% in the same period.
The broader trend indicates a strong appetite for smaller companies, with the small and mid-cap mutual fund category hitting an 11-month high in new investor accounts in July. Another example of this trend was Diamond Power Infrastructure, which saw its mutual fund holdings increase 105 times in just one month, with ₹1,300 crore deployed into the firm.
While the influx of capital from mutual funds is often viewed as a positive sign of institutional confidence, investors should maintain a balanced perspective. The mid-cap sector is currently facing valuation concerns, with many analysts warning that prices have run up significantly. When valuations rise, companies may become more sensitive to any negative market news or missed performance targets.
For investors following the inflows into Biocon, it is important to examine the company's financial health alongside the buying activity. Despite the positive market sentiment, the company reported a significant decline of 63.45% in its consolidated net profit for the quarter ending March 2026. The stock's performance in the coming months will likely depend on whether the company can improve its operational efficiency and profit margins to align with the higher valuation.
Looking ahead, the market will likely focus on whether these companies can deliver on earnings growth. With volatility in the small and mid-cap space remaining a possibility, the key monitorable for investors will be upcoming quarterly results, which will clarify if the recent price appreciation is supported by actual business growth or if it is primarily driven by liquidity and market momentum.